Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. 60-56-0, formula is C4H6N2S, Name is 1-Methyl-1H-imidazole-2(3H)-thione. Their solubility in alcohol is lower than that in water and decreases with increasing molecular weight of the alcohols . Safety of 1-Methyl-1H-imidazole-2(3H)-thione.
di Filippo, Luigi;Castellino, Laura;Giustina, Andrea research published 《 Occurrence and response to treatment of Graves’ disease after COVID vaccination in two male patients》, the research content is summarized as follows. COVID-19 had dramatic impact worldwide and various vaccines anti-SARS-CoV-2 were rapidly developed. Despite a good safety profile in clin. trials, rare and severe side effects of vaccines have been reported, including thyroid dysfunctions. In particular, occurrence of Graves’ disease (GD) post-vaccination with Tozinameran (Pfizer-BioNTech) was reported in three female subjects and only one male prevalently in young-adult age somewhat reflecting the epidemiol. age and sex distribution of the disease. Reported here is the occurrence and the response to treatment of GD in two male patients after Vaxzevria (Oxford-AstraZeneca) SARS-CoV-2 vaccinations. Case 1 is of a previously healthy, past-smoker, 32-yr-old male patient, without any personal or family history of endocrine and autoimmune diseases, ten days after the second dose of Vaxzevria vaccine developed anxiety, tachycardia and palpitations, without signs of orbitopathy or local pain. Tyroid-function tests revealed decreased TSH with elevated free-T4 and free-T3 levels and elevated thy rotropin recept or-antibodies (TRAbs). After three months of therapy his thyroid function is currently normal and TRAbs levels halved on 100 mg/daily dose of propylthiouracil. Case 2 is of a reviously healthy, past-smoker, 35-yr-old male patient, without any personal or family history of endocrine and autoimmune disease, 5 days after the first dose of Vaxzevria vaccine developed headache, nausea, asthenia, palpitations, tachycardia, mild eyes-redness and superior palpebral retraction. Thyroid-function tests revealed sup- pressed TSH with elevated free-T4 and free-T3 levels and elevated TRAbs. After three months of therapy his thyroid function and TRAbs levels are currently normal on 5 mg/daily dose of thiamazole. It cannot be excluded also a possible influence of vitamin D status on GD occurrence after COVID-19 vaccination, although data on VD status in our patients were not available. In conclusion, although COVID-19 vaccination is currently not contraindicated in patients with stable autoimmune endocrine diseases,this data suggest a note of caution in administering a further vaccine dose to patients that developed GD in the first weeks after vaccination. Moreover, it is suggested to carefully consider if submitting patients with recent onset or non-stable GD to all types of COVID-19 vaccination.
60-56-0, Methimazole is an antithyroid compound found to have antioxidant properties. Methimazole inhibits activation of the IFN-g-induced Janus kinase (JAK)/STAT signaling pathway in FRTL-5 thyroid cells, which may account for its immunodolulatory effects. Additionally, methimazole is an inhibitor of thyroperoxidase.
Methimazole is a thiourea antithyroid agent that prevents iodine organification, thus inhibiting the synthesis of thyroxine. Antihyperthyroid.
Methimazole is an inhibitor of thyroid hormone synthesis. It is a substrate for thyroid peroxidase that traps oxidized iodide, preventing its use by thyroglobulin for thyroid hormone synthesis. Methimazole (0.4 mg/kg) inhibits the absorption of radiolabeled iodide by the thyroid gland in rats by 80.9%.3 It reduces the incidence of lymphocytic thyroiditis in the insulin-dependent type 1 diabetic BB/W rat. Methimazole has been used to induce hypothyroidism in mice. Formulations containing methimazole have been used in the treatment of hyperthyroidism.
Methimazole is a thyreostatic compound, and an antihormone, which is widely used in medicine for the treatment of hyperthyroidism.
Methimazole is a thioamide inhibitor of the enzyme thyroid peroxidase (TPO), with antithyroid activity. Upon administration, methimazole inhibits the metabolism of iodide and the iodination of tyrosine residues in the thyroid hormone precursor thyroglobulin by TPO; this prevents the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4).
Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course.
Methimazole, also known as tapazole or danantizol, belongs to the class of organic compounds known as imidazolethiones. These are aromatic compounds containing an imidazole ring which bears a thioketone group. Methimazole is a drug which is used for the treatment of hyperthyroidism, goiter, graves disease and psoriasis. Methimazole is soluble (in water) and a very weakly acidic compound (based on its pKa). Methimazole has been detected in multiple biofluids, such as urine and blood. Methimazole can be converted into methimazole S-oxide., Safety of 1-Methyl-1H-imidazole-2(3H)-thione
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem